Table 3. Comparison of Heart Transplant Donors, Recipients and Outcomes.
| Characteristic | No. (%) | P Value | |
|---|---|---|---|
| dd-HCV (n = 67) | No dd-HCV (n = 13) | ||
| Donor HCV profile | |||
| Ab-positive/NAT-positive | 66 (98.5) | 2 (1.5) | NA |
| Ab-positive/NAT-negative | 0 (0.0) | 10 (76.9) | |
| Ab-negative/NAT-positive | 1 (1.5) | 1 (1.5) | |
| Severe PGD | 11 (16.4) | 0 (0.0) | .20 |
| Hospital length of stay post-HT, median (IQR), d | 15 (12-23) | 17 (14-19) | .79 |
| Acute rejection requiring treatment | 11 (16.4) | 2 (15.4) | >.99 |
| CAV at 1 y post-HTa | |||
| CAV-1 | 7 (24.1) | 1 (11.1) | .54 |
| CAV-2 | 1 (3.4) | 1 (11.1) | |
| CAV-3 | 1 (3.4) | 0 (0.0) | |
| Retransplant | 1 (1.5) | 1 (7.7) | .30 |
| Survival post-HT, % | |||
| 30-d | 92.5 | 100 | .32 |
| 1-y | 90.4 | 91.7 | .79 |
| Donor HCV Status | HCV-positive (n = 80) | HCV-negative (n = 159) | |
| Donor age, median (IQR), y | 32 (27-37) | 31 (23-38) | .51 |
| Location of death by UNOS region | |||
| 1 | 3 (3.7) | 0 (0.0) | <.001 |
| 2 | 9 (11.3) | 3 (1.9) | |
| 3 | 18 (22.5) | 24 (15.0) | |
| 4 | 5 (6.3) | 8 (5.0) | |
| 7 | 5 (6.3) | 5 (3.1) | |
| 8 | 2 (2.5) | 2 (1.3) | |
| 9 | 1 (1.3) | 0 (0.0) | |
| 10 | 6 (7.5) | 2 (13) | |
| 11 | 31 (38.8) | 115 (72.3) | |
| Recipient | |||
| Age, median (IQR), y | 54 (46-62) | 54 (42-63) | .74 |
| Male sex | 57 (71.3) | 120 (75.5) | .48 |
| Severe PGD | 11 (13.7) | 5 (3.1) | .002 |
| Hospital length of stay post-HT, median (IQR), d | 15 (12-23) | 15.5 (11-20) | .53 |
| Acute rejection requiring treatment | 13 (16.3) | 43 (27.0) | .06 |
| CAV at 1 y post-HTa | |||
| CAV-1 | 8 (21) | 11 (10.8) | .23 |
| CAV-2 | 2 (5.0) | 2 (2.0) | |
| CAV-3 | 1 (2.6) | 3 (2.9) | |
| Retransplant | 2 (2.5) | 1 (0.63) | .26 |
| Survival rates post-HT, % | |||
| 30-d | 93.7 | 96.2 | .39 |
| 1-y | 90.7 | 90.5 | .88 |
Abbreviations: Ab, antibody; CAV, coronary allograft vasculopathy; dd-HCV, donor-derived hepatitis C virus; HCV, hepatitis C virus; HT, heart transplant; IQR, interquartile range; NAT, nucleic acid test; PGD, primary graft dysfunction; UNOS, United Network for Organ Sharing.
a
Data for CAV were available for 29 patients in the dd-HCV cohort, 9 patients in the no dd-HCV cohort, 38 patients in the HCV-positive donor cohort, and 102 patients in the HCV-negative donor cohort.